Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.18    0.00 (0.00%)
Bid:
0.17
Ask:
0.19
Spread: 0.02 (11.765%)
Market Cap: £2.38m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Convertible Loan Note Offer

18 Jul 2006 15:48

Azure Holdings PLC18 July 2006 Azure Holdings plc (the "Company") Convertible Loan Note Offer The Company announces that it has today issued a letter to holders of ordinaryshares of 1p each in the Company ("Ordinary Shares"), on the share register ofthe Company on 17 July 2006, offering them the opportunity to participate in thesubscription of up to £1,200,000 nominal unsecured convertible loan stock 2008("Loan Stock"). The Loan Stock is being offered following discussions regarding a proposedacquisition by the Company ("Acquisition"). The proposed target for theAcquisition is ValiRX Limited ("ValiRX"), a biopharmaceutical developmentcompany. Discussions with ValiRX are progressing and the directors of theCompany hope to complete a reverse takeover under the AIM rules before 30September 2006. The principal terms of the Loan Stock are as follows: 1 Unless previously converted or repaid, the Loan Stock isrepayable 24 months from the date of the Loan Stock instrument under which it iscreated (the "Instrument") or at any time after 31 October 2006 at the Company'soption. 2 In partial consideration for the Loan Stock holderssubscribing for Loan Stock, a premium ("Premium") of £2 for each £1 nominal ofLoan Stock is payable, unless previously converted or paid, 24 months from thedate of the Instrument, or at any time after 31 October 2006 at the Company'soption. 3 Interest is payable from 1 November 2006 on the amount ofthe Loan Stock at the rate of two per cent. over the base rate of the Bank ofScotland plc from time to time. Interest is payable twice yearly. The firstinterest period will run from 1 November 2006 to 31 March 2007. 4 The conversion of Loan Stock ("Conversion") into OrdinaryShares is conditional upon approval by shareholders of resolutions to allotshares and disapply pre-emption rights; and if appropriate, the approval by avote of independent shareholders taken on a poll of any waiver granted by thePanel on Takeovers and Mergers of any obligation under rule 9 of the City Codeon Takeovers and Mergers which may arise from such Conversion (together the "Conversion Event") 5 Immediately prior to the Conversion Event, the Loan Stockis deemed repayable and the Premium is deemed payable. 6 On the Conversion Event, the Loan Stock and the Premiumwhich has not been repaid or paid as the case may be, will be converted intoOrdinary Shares in the capital of the Company at the rate of 100 Ordinary Sharesof the Company for each £1 otherwise due for repayment or payment. 7 So far as it is lawfully able to do so, the Company willnotify the Loan Stock holders at least 10 days in advance of the likelyoccurrence of the Conversion Event. 8 The Loan Stock is transferable in multiples of £10,000. 9 The Company is obliged to repay the Loan Stock and pay thePremium on the occurrence of certain events, including certain insolvencyevents. 10 Decisions relating to the Loan Stock are to be taken by a writtenresolution of the holders of at least two thirds in nominal value of theoutstanding Loan Stock. Applications for the Loan Stock may only be made for a minimum of £1,000 nominaland in multiples of £1,000. Applications for the Loan Stock are to be receivedby the Company at One Great Cumberland Place, London W1H 7AL by 3.00pm on 31July 2006. A copy of the letter despatched to shareholders and the Instrument are availablefor inspection, on request, at Halliwells LLP, 1 Threadneedle Street, LondonEC2R 8AW during normal business hours on any weekdays, Saturdays, Sundays andpublic holidays excluded, for one month from today. For further information, please contact: Barry Gold, Azure Holdings plcTel: 07768 948 928 David Youngman, WH Ireland Limited Tel: 0161 832 2174 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
11th Aug 20177:00 amRNSConvertible Loan Facility
2nd Aug 20177:00 amRNSConversion of Loan Note
28th Jul 20177:00 amRNSLicencing Agreement
22nd Jun 20177:00 amRNSFormation of & Appointments to an Advisory Board
15th Jun 20177:00 amRNSValiSeek Development Update - Recruitment Closes
1st Jun 201711:00 amRNSYorkville CLN Conversion
31st May 201711:00 amRNSHardman Research:Developing novel cancer therapies
30th May 201710:34 amRNSResult of AGM
24th May 20177:00 amRNSNOTIFICATION OF AUSTRALIAN PATENT ALLOWANCE
5th May 20175:28 pmRNSNotice of AGM
5th May 20177:00 amRNSFinal Results
27th Apr 201710:07 amRNSRe: SHARES Magazine Supplement on ValiRx website
19th Apr 20179:00 amRNSChange of Registered Office
15th Mar 20179:33 amRNSDirector/PDMR Shareholding
8th Mar 20177:00 amRNSValiSeek Clinical Development Update
2nd Mar 20177:00 amRNSDirector/PDMR Shareholding
1st Mar 20171:37 pmRNSPlacing to raise £1.16m and Proposed Subscription
28th Feb 20177:00 amRNSPublication of Peer-Reviewed Articles on VAL401
11th Jan 20177:00 amRNSCLINICAL TRIAL UPDATE - Positive VAL201 Results
30th Dec 20167:00 amRNSYorkville CLN Conversion
8th Dec 20167:00 amRNSEuropean Patent Granted for Lead Compound VAL201
2nd Dec 20164:15 pmRNSConvertible Loan Facility
1st Dec 20167:00 amRNSValiSeek Clinical Development Update
29th Nov 20167:00 amRNSQuarterly Update on Clinical Developments
3rd Nov 20167:00 amRNSValiSeek Clinical Development Update
28th Oct 20169:00 amRNSCorporate Video re Clinical Status Q4, 2016
25th Oct 20167:00 amRNSPatent Update
13th Oct 20164:20 pmRNSHolding(s) in Company
13th Oct 20164:20 pmRNSHolding(s) in Company
13th Oct 20167:00 amRNSUpdate on Recent Presentations
12th Oct 201611:15 amRNSResult of General Meeting
5th Oct 20163:42 pmRNSCLN Conversion
28th Sep 201611:09 amRNSNotice of GM
27th Sep 20167:00 amRNSHalf-year Report
26th Sep 20167:00 amRNSValiRx selected for The Parliamentary Review 2016
13th Sep 20167:00 amRNSQuarterly Update on Clinical Developments
2nd Sep 20162:10 pmRNSPlacing, issue of warrants & Convertible Loan
11th Aug 20167:00 amRNSValiSeek Clinical Development Update
4th Aug 201611:32 amRNSIssue of Equity
28th Jul 20167:00 amRNSNotification of New Zealand Patent Grant Allowance
26th Jul 20167:00 amRNSIssue of Equity and Bracknor Facility Update
14th Jul 20167:00 amRNSValiSeek Clinical Development Update
12th Jul 201611:58 amRNSResult of GM
7th Jul 20167:00 amRNSSale of TRAC Technology Rights for EUR 0.8 million
27th Jun 20167:00 amRNSNotice of GM
20th Jun 20162:24 pmRNSResult of AGM
7th Jun 20167:00 amRNSQuarterly Update
7th Jun 20167:00 amRNSAppointment of Joint Broker
26th May 20168:00 amRNSPosting of Annual Report & Notice of AGM
19th May 201611:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.